Drug class in one race
CDK2/4/6/CDK4 drugs for HR+/HER2- Metastatic Breast Cancer
2 tracked CDK2/4/6/CDK4 drugs in the HR+/HER2- Metastatic Breast Cancer race. The class explanation lives on the CDK2/4/6/CDK4 page; the full indication pipeline across every mechanism is on the HR+/HER2- Metastatic Breast Cancer page.
1 Phase 31 Phase 2/3
Head-to-head evidence: Culmerciclib vs SPH4336